Lyra Therapeutics Announces Positive Phase 3 Trial Results

Lyra Therapeutics ( (LYRA) ) has shared an update.

On June 2, 2025, Lyra Therapeutics announced positive results from the ENLIGHTEN 2 Phase 3 clinical trial of LYR-210, which met its primary and key secondary endpoints for treating chronic rhinosinusitis (CRS) at 24 weeks. The trial demonstrated statistically significant improvements in symptoms for patients both with and without nasal polyps, positioning Lyra to advance regulatory strategies and potentially become a leader in CRS treatment.

The most recent analyst rating on (LYRA) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Lyra Therapeutics stock, see the LYRA Stock Forecast page.

Spark’s Take on LYRA Stock

According to Spark, TipRanks’ AI Analyst, LYRA is a Neutral.

Lyra Therapeutics faces significant financial and technical challenges, reflected in its low score. Persistent losses and negative cash flows highlight financial instability, while bearish technical indicators suggest continued downward pressure on the stock. The negative P/E ratio and lack of dividend yield further underscore the valuation concerns. Strategic adjustments are essential to improve the company’s financial position and investor appeal.

To see Spark’s full report on LYRA stock, click here.

More about Lyra Therapeutics

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS).

Average Trading Volume: 69,165

Technical Sentiment Signal: Sell

Current Market Cap: $6.53M

Find detailed analytics on LYRA stock on TipRanks’ Stock Analysis page.